Heat Biologics CEO Jeff Wolf talks with Contagion about the firm's effort to develop a vaccine for the coronavirus which can potentially be administered for some seniors by taking advantage of prior immune mechanisms.
Part 2
Heat Biologics CEO Jeff Wolf talks with Contagion about the firm's effort to develop a vaccine for the coronavirus which can potentially be administered for some seniors.
"We have a very unique vaccine," Wolf argues, pointing to the potential to use the company's GP-96 vaccine platform in older populations.
[Bio provided by Heat Biologics]
Jeffrey Wolf is founder and CEO of Heat Biologics. He also founded Seed-One Ventures, a firm focused on the systematic formation and management of new biomedical companies based upon breakthrough research.
Throughout his career, Mr. Wolf has specialized in building new life-science companies from the ground up and has played an active role in supporting the growth of his companies.
Mr. Wolf's start-ups include Avigen (co-founder and director), a NASDAQ-listed gene therapy company; TyRx Pharma (co-founder and chairman), which was focused on the development of novel bio-compatible polymers and recently sold to Medtronic and EluSys Therapeutics (founder and CEO), focused on the development of novel antibodies against infectious diseases.
Mr. Wolf received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law and his B.A. from the University of Chicago, where he graduated with honors in economics.
